-
Chelsea win as Bayern and Madrid draw in Women's Champions League
-
US Fed holds interest rates steady despite 'too high' inflation
-
Made with munitions from the Falklands War, a 'Chalice of Peace' for the pope
-
Rwanda cannot be blamed for what happens in DR Congo, FM says
-
Pioneering US labor leader Dolores Huerta dies at 96
-
Inter leave it late again in Serie A as Bologna sink AC Milan
-
Italian PM slams 'shameful' release of alleged protest organiser
-
Bolsonaro's escape to the US: How it happened
-
Hollywood producer Kennedy to head LA28 Olympic ceremony plans
-
Russell calls on Scotland to 'kick on' and beat big teams
-
Djokovic wins Basel opener to boost ATP Finals bid
-
Airbus aims for record deliveries despite disappointing quarter
-
US Fed holds interest rates steady despite surging inflation
-
Cuba wins UN vote against US embargo with weakest backing in 30 years
-
Chiefs sign ex-Ravens kicker suspended over sex allegations
-
Real Madrid, La Liga apology over Mbappe shows power of Chinese market
-
Inglis and Carey put Australia in command of South Africa decider
-
From Gaza to Ramallah, Palestinians see little hope in Israeli vote
-
92-year-old US judge handling Maduro case dies
-
US labor leader Dolores Huerta dead: family
-
Perez extends Cadillac deal to 2029
-
Investors turn cautious ahead of tech results, Fed update on rates
-
Arab Israelis proud of high election turnout, uncertain for future
-
'Cruise for life' strands passengers in Cambodia as operator goes bust
-
Inglis, Carey put Australia in command of South Africa decider
-
Bolsonaro flees Brazil for US after election defeat
-
French firm Safran helps build aircraft wings of the future in UK factory
-
A throne on wheels, popemobiles star in new Vatican show
-
Ceasefire in Russia-occupied Ukrainian city holds for second day
-
Spain high-speed train crash kills 68, injures over 100
-
Canada hikes rates to contain oil price surge caused by Iran war
-
UK woman drugged by husband tells rape trial she woke up bound
-
World Bank warns of worsening food insecurity as commodity prices soar
-
Clean-up starts as Serbian students movement prepares to govern
-
Mona Lisa scrubbed from Syrian textbooks as critics slam conservative drift
-
Flavio Bolsonaro: right-wing heir falls from presidential hopeful to exile
-
Bolsonaro flees Brazil for US after election defeat: AFP
-
UK budget lifts bank tax to offset surging energy bills
-
Brazil's Bolsonaros: between power, prison, and exile
-
Spain high-speed train collision kills 64, injures over 100
-
Israel president urges against new vote despite inconclusive result
-
Brazil's Bolsonaro lands in Florida after election defeat: AFP
-
Eala recovers to move into Tokyo quarter-finals
-
Russia woos African leaders at Moscow summit
-
COPs 'bunch of baloney' says Panama as it vies to host nature summit
-
Local ceasefire in Russia-occupied Ukrainian city holds for second day
-
Denmark mulls banning turbo chickens
-
Odegaard urges Arsenal to move on after Fleetwood upset
-
Nintendo producer 'all nervous' as Zelda classic remake hits shelves
-
Japan, Germany leaders target closer ties on critical minerals
US medical agency will scale back testing on monkeys
The United States will scale back certain drug-safety testing requirements on monkeys, federal regulators said Tuesday, marking the latest step by President Donald Trump's administration to limit the use of animals in research.
Under new draft guidance from the Food and Drug Administration, computer models, lab-grown mini-organs, and human studies will replace the use of non-human primates in testing monoclonal antibodies -- lab-engineered proteins used to treat cancers, autoimmune conditions and other diseases.
"We are delivering on our roadmap commitment to eliminate animal testing requirements in drug evaluation and our promise to accelerate cures and meaningful treatments for Americans," FDA Commissioner Marty Makary said in a statement.
The statement added that typical nonclinical programs involving monoclonal antibodies could include more than 100 macaque monkeys -- apes are no longer used in any invasive research in the US -- yet often do not yield human-approved treatments.
The move was welcomed by animal-advocacy groups.
Zaher Nahle, a former animal researcher who is now the senior scientific advisor for nonprofit Center for a Humane Economy, told AFP the move was an "important step."
"These primates are not reliable in terms of predicting the toxicity, so you can get at least equal or better results in terms of your accuracy in predicting toxicology using other approaches," he added.
What's more, he noted, studies show that more than 90 percent of drugs deemed safe and effective in animals fail to win approval for human use.
The FDA's announcement follows a report in the journal Science last month that the Centers for Disease Control and Prevention would close its primate labs.
It "moves us one step closer to wiping out the federal government's wasteful monkey business," Justin Goodman of White Coat Waste Project told AFP.
But the National Institutes of Health -- the country's primary biomedical research agency -- remains a notable "outlier," he added. According to public data, 7,700 primates are confined in federal government labs and breeding facilities, of which 6,700 are at NIH.
Advocates of animal research have pushed back.
"Poorly planned transitions -- including premature study termination -- can place animals at serious risk and may undermine years of scientific investment intended to strengthen public health preparedness and advance lifesaving medical progress," advocacy group Americans for Medical Progress said after the CDC news was reported.
Proponents of animal testing say the research has been indispensable for major medical advances, including vaccines for diphtheria, yellow fever, measles and Covid-19.
Critics counter that decades-old laws have created regulatory lock-in, that publication incentives reward animal studies in top journals, and that a lucrative "animal-industrial complex" has helped entrench the status quo.
K.Hofmann--VB